Polypill Treatment Offers High Value in Low-Income, Underserved Population
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 13, 2025 -- Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to a study published online Jan. 8 in JAMA Cardiology.
Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a health care sector perspective, adopting a time horizon of 10 years. In the base case analysis, polypill treatment was priced at $463 per year. An SCCS Polypill Trial-representative cohort of 100,000 individuals and all trial-eligible non-Hispanic Black adults were analyzed.
The researchers found that polypill treatment was projected to yield a mean of 1,190 additional quality-adjusted life-years (QALYs) compared with usual care in the trial-representative cohort of 100,000 individuals, at a cost of about $10,152,000. The cost of polypill treatment was estimated at $8,560 per QALY gained compared with usual care, and had high value in 99 percent of simulations. Polypill treatment was estimated to be of high value and cost-saving when priced at $559 or less per year and $443 or less per year, respectively. Polypill treatment remained high value in almost all sensitivity analyses. Polypill treatment offered high value in a secondary analysis of 3,602,427 trial-eligible non-Hispanic Black U.S. adults, with an estimated cost of $13,400 per QALY gained.
"In this economic evaluation, using a computer simulation model, we projected that the polypill would be high value in this population if priced based on its component medications ($463 per year) and may reduce income-related health disparities," the authors write.
One author disclosed ties to Boehringer Ingelheim.
Editor's Note (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Helping Others Linked to Higher Level of Cognitive Function
THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...
Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes
THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.